Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 20, 2024
Emerging Company Profile

Reverb: redirecting endogenous cytokines to tumors

Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue
BioCentury | Jun 2, 2023
Emerging Company Profile

Actym: programming microbes to treat solid tumors

Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
BioCentury | Dec 17, 2022
Discovery & Translation

Synthetic engineering of immune cells; plus Genentech’s bispecific for Netherton and more

BioCentury’s roundup of translational news
BioCentury | Nov 11, 2022
Discovery & Translation

S&K’s small molecule TNF inhibitor; plus Actym’s engineered bacteria platform and more

BioCentury’s roundup of translational news
BioCentury | Mar 15, 2021
Product Development

As investors welcome early efficacy signal, Rubius sees platform validation in results

Biotech assessing next steps for solid tumor program after pair of responses
BioCentury | Jan 25, 2019
Product R&D

Rubius turns immunotherapy red

Why Rubius is gearing its RBC therapies to mimic immune cell interactions
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

Cytokines are emerging as a logical combination partner to boost PD-1 responses
Items per page:
1 - 10 of 27